Pictorial review of multiparametric MRI in bladder urothelial carcinoma with variant histology: pearls and pitfalls.
Contrast Media
Diffusion
Magnetic Resonance Imaging
Neoplasm Staging
Transurethral Resection of Bladder
Urinary Bladder Neoplasms
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
07 Jun 2024
07 Jun 2024
Historique:
received:
05
04
2024
accepted:
17
05
2024
revised:
15
05
2024
medline:
7
6
2024
pubmed:
7
6
2024
entrez:
7
6
2024
Statut:
aheadofprint
Résumé
Bladder cancer (BC), predominantly comprising urothelial carcinomas (UCs), ranks as the tenth most common cancer worldwide. UCs with variant histology (variant UC), including squamous differentiation, glandular differentiation, plasmacytoid variant, micropapillary variant, sarcomatoid variant, and nested variant, accounting for 5-10% of cases, exhibit more aggressive and advanced tumor characteristics compared to pure UC. The Vesical Imaging-Reporting and Data System (VI-RADS), established in 2018, provides guidelines for the preoperative evaluation of muscle-invasive bladder cancer (MIBC) using multiparametric magnetic resonance imaging (mpMRI). This technique integrates T2-weighted imaging (T2WI), dynamic contrast-enhanced (DCE)-MRI, and diffusion-weighted imaging (DWI) to distinguish MIBC from non-muscle-invasive bladder cancer (NMIBC). VI-RADS has demonstrated high diagnostic performance in differentiating these two categories for pure UC. However, its accuracy in detecting muscle invasion in variant UCs is currently under investigation. These variant UCs are associated with a higher likelihood of disease recurrence and require precise preoperative assessment and immediate surgical intervention. This review highlights the potential value of mpMRI for different variant UCs and explores the clinical implications and prospects of VI-RADS in managing these patients, emphasizing the need for careful interpretation of mpMRI examinations including DCE-MRI, particularly given the heterogeneity and aggressive nature of variant UCs. Additionally, the review addresses the fundamental MRI reading procedures, discusses potential causes of diagnostic errors, and considers future directions in the use of artificial intelligence and radiomics to further optimize the bladder MRI protocol.
Identifiants
pubmed: 38847848
doi: 10.1007/s00261-024-04397-3
pii: 10.1007/s00261-024-04397-3
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH/NCI Cancer Center
ID : P30 CA008748 (MSK)
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Choy B, Tretiakova M, Zynger DL (2024) What’s new in genitourinary pathology 2023: WHO 5th edition updates for urinary tract, prostate, testis, and penis. J Pathol Transl Med 58:45–8.
pubmed: 38145904
doi: 10.4132/jptm.2023.12.11
Hansel DE, Amin MB, Comperat E, Cote RJ, Knüchel R, Montironi R, et al (2013) A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol 63:321–32.
pubmed: 23088996
doi: 10.1016/j.eururo.2012.10.008
Wang G, McKenney JK (2019) Urinary Bladder Pathology: World Health Organization Classification and American Joint Committee on Cancer Staging Update. Arch Pathol Lab Med 143:571–7.
pubmed: 30044124
doi: 10.5858/arpa.2017-0539-RA
Black PC, Brown GA, Dinney CP (2009) The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 27:3–7.
pubmed: 18367107
doi: 10.1016/j.urolonc.2007.07.010
Alfred Witjes J, Max Bruins H, Carrión A, Cathomas R, Compérat E, Efstathiou JA, et al (2024) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol 85:17–31.
pubmed: 37858453
doi: 10.1016/j.eururo.2023.08.016
Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, et al (2018) Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 74:294–306.
pubmed: 29755006
pmcid: 6690492
doi: 10.1016/j.eururo.2018.04.029
Panebianco V, Briganti A, Boellaard TN, Catto J, Comperat E, Efstathiou J, et al (2023) Clinical application of bladder MRI and the Vesical Imaging-Reporting And Data System. Nat Rev Urol. https:// https://doi.org/10.1038/s41585-023-00830-2 .
doi: 10.1038/s41585-023-00830-2
pubmed: 38036666
Woo S, Panebianco V, Narumi Y, Del Giudice F, Muglia VF, Takeuchi M, et al (2020) Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol 3:306–15.
pubmed: 32199915
pmcid: 7293940
doi: 10.1016/j.euo.2020.02.007
Del Giudice F, Flammia RS, Pecoraro M, Moschini M, D’Andrea D, Messina E, et al (2022) The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. World J Urol 40:1617–28.
pubmed: 35294583
pmcid: 9237003
doi: 10.1007/s00345-022-03969-6
Arita Y, Shigeta K, Akita H, Suzuki T, Kufukihara R, Kwee TC, et al (2021) Clinical utility of the Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer between radiologists and urologists based on multiparametric MRI including 3D FSE T2-weighted acquisitions. Eur Radiol 31:875–83.
pubmed: 32829418
doi: 10.1007/s00330-020-07153-5
Wang H, Luo C, Zhang F, Guan J, Li S, Yao H, et al (2019) Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion. Radiology 291:668–74.
pubmed: 31012814
doi: 10.1148/radiol.2019182506
Jazayeri SB, Dehghanbanadaki H, Hosseini M, Taghipour P, Alam MU, Balaji KC, et al (2022) Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) in suspected muscle invasive bladder cancer: A systematic review and diagnostic meta-analysis. Urol Oncol 40:45–55.
pubmed: 34895996
doi: 10.1016/j.urolonc.2021.11.008
Arita Y, Yoshida S, Shigeta K, Kwee TC, Edo H, Okawara N, Hashimoto M, Ishii R, Ueda R, Mikami S, Fujiwara M, Waseda Y, Kikuchi E, Fujii Y, Jinzaki M (2023) Diagnostic value of the vesical imaging-reporting and data system in bladder urothelial carcinoma with variant histology. Eur Urol Oncol 6(1):99–102
pubmed: 35933266
doi: 10.1016/j.euo.2022.07.006
Arita Y, Kwee TC, Woo S, Shigeta K, Ishii R, Okawara N, et al (2023) Biparametric versus Multiparametric Magnetic Resonance Imaging for Assessing Muscle Invasion in Bladder Urothelial Carcinoma with Variant Histology Using the Vesical Imaging-Reporting and Data System. Eur Urol Focus. https://doi.org/10.1016/j.euf.2023.08.004 .
doi: 10.1016/j.euf.2023.08.004
pubmed: 37633790
Jafari NV, Rohn JL (2022) The urothelium: a multi-faceted barrier against a harsh environment. Mucosal Immunol 15:1127–42.
pubmed: 36180582
pmcid: 9705259
doi: 10.1038/s41385-022-00565-0
Shin K, Lim A, Odegaard JI, Honeycutt JD, Kawano S, Hsieh MH, et al (2014) Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat Cell Biol 16:469–78.
pubmed: 24747439
pmcid: 4196946
doi: 10.1038/ncb2956
Andersson KE, McCloskey KD (2014) Lamina propria: the functional center of the bladder? Neurourol Urodyn 33:9–16.
pubmed: 23847015
doi: 10.1002/nau.22465
Narumi Y, Kadota T, Inoue E, Kuriyama K, Horinouchi T, Kasai K, et al (1993) Bladder wall morphology: in vitro MR imaging-histopathologic correlation. Radiology 187:151–5.
pubmed: 8451403
doi: 10.1148/radiology.187.1.8451403
Johnson W, Taylor MB, Carrington BM, Bonington SC, Swindell R (2007) The value of hyoscine butylbromide in pelvic MRI. Clin Radiol 62:1087–93.
pubmed: 17920868
doi: 10.1016/j.crad.2007.05.007
Caglic I, Panebianco V, Vargas HA, Bura V, Woo S, Pecoraro M, et al (2020) MRI of Bladder Cancer: Local and Nodal Staging. J Magn Reson Imaging 52:649–67.
pubmed: 32112505
doi: 10.1002/jmri.27090
Panebianco V, De Berardinis E, Barchetti G, Simone G, Leonardo C, Grompone MD, et al (2017) An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol 27:3759–66.
pubmed: 28181054
doi: 10.1007/s00330-017-4758-3
Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Kawai T, et al (2009) Urinary bladder cancer: diffusion-weighted MR imaging–accuracy for diagnosing T stage and estimating histologic grade. Radiology. 251:112-21.
pubmed: 19332849
doi: 10.1148/radiol.2511080873
Wang F, Jin D, Hua XL, Zhao ZZ, Wu LM, Chen WB, et al (2018) Investigation of diffusion kurtosis imaging for discriminating tumors from inflammatory lesions after treatment for bladder cancer. J Magn Reson Imaging 48:259–65.
pubmed: 29232021
doi: 10.1002/jmri.25924
van der Pol CB, Chung A, Lim C, Gandhi N, Tu W, McInnes MDF, et al (2018) Update on multiparametric MRI of urinary bladder cancer. J Magn Reson Imaging 48:882–96.
pubmed: 30221801
doi: 10.1002/jmri.26294
Hayashi N, Tochigi H, Shiraishi T, Takeda K, Kawamura J (2000) A new staging criterion for bladder carcinoma using gadolinium-enhanced magnetic resonance imaging with an endorectal surface coil: a comparison with ultrasonography. BJU Int 85:32–6.
pubmed: 10619941
doi: 10.1046/j.1464-410x.2000.00358.x
Hoegger MJ, Strnad BS, Ballard DH, Siegel CL, Shetty AS, Weimholt RC, et al (2023) Urinary Bladder Masses, Rare Subtypes, and Masslike Lesions: Radiologic-Pathologic Correlation. Radiographics 43:e220034.
pubmed: 36490210
doi: 10.1148/rg.220034
Woo S, Suh CH, Kim SY, Cho JY, Kim SH, Moon MH (2018) Head-to-Head Comparison Between Biparametric and Multiparametric MRI for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol 211:W226–w41.
pubmed: 30240296
doi: 10.2214/AJR.18.19880
Tong P, Sun D, Chen G, Ni J, Li Y (2015) Biparametric magnetic resonance imaging-based radiomics features for prediction of lymphovascular invasion in rectal cancer. BMC Cancer 23:61.
doi: 10.1186/s12885-023-10534-w
Kanda T, Matsuda M, Oba H, Toyoda K, Furui S (2015) Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology 277:924–5.
pubmed: 26599932
doi: 10.1148/radiol.2015150697
McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, et al (2015) Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology 275:772–82.
pubmed: 25742194
doi: 10.1148/radiol.15150025
Ye L, Chen Y, Xu H, Xie H, Yao J, Liu J, et al (2022) Biparametric magnetic resonance imaging assessment for detection of muscle-invasive bladder cancer: a systematic review and meta-analysis. Eur Radiol 32:6480–92.
pubmed: 35362750
doi: 10.1007/s00330-022-08696-5
Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A, et al (2013) Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer 49:1889–97.
pubmed: 23466126
doi: 10.1016/j.ejca.2013.02.001
Donaldson SB, Bonington SC, Kershaw LE, Cowan R, Lyons J, Elliott T, et al (2013) Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. Eur J Radiol 82:2161–8.
pubmed: 24034835
doi: 10.1016/j.ejrad.2013.08.008
Schrier BP, Peters M, Barentsz JO, Witjes JA (2006). Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol 49:698–703.
pubmed: 16464531
doi: 10.1016/j.eururo.2006.01.022
Hafeez S, Horwich A, Omar O, Mohammed K, Thompson A, Kumar P, et al (2015) Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. Br J Cancer 112:1626–35.
pubmed: 25897675
pmcid: 4430712
doi: 10.1038/bjc.2015.109
Liu Y, Bui MM, Xu B (2017) Urothelial Carcinoma With Squamous Differentiation Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis. Cancer Control 24:78–82.
pubmed: 28178718
doi: 10.1177/107327481702400113
Shah RB, Montgomery JS, Montie JE, Kunju LP (2013). Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol 31:1650–5.
pubmed: 22608543
doi: 10.1016/j.urolonc.2012.04.009
Antunes AA, Nesrallah LJ, Dall’Oglio MF, Maluf CE, Camara C, Leite KR, et al (2007) The role of squamous differentiation in patients with transitional cell carcinoma of the bladder treated with radical cystectomy. Int Braz J Urol 33:339–45; discussion 46.
pubmed: 17626650
doi: 10.1590/S1677-55382007000300006
Honma I, Masumori N, Sato E, Takayanagi A, Takahashi A, Itoh N, et al (2004) Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology 64:744–8.
pubmed: 15491713
doi: 10.1016/j.urology.2004.05.003
Mühlbauer J, Stein R, Younsi N (2021) Bladder cancer in patients with spina bifida: a serious risk. World J Urol 39:1531–7.
pubmed: 32632554
doi: 10.1007/s00345-020-03338-1
Gelfand M, Weinberg RW, Castle WM (1967) Relation between carcinoma of the bladder and infestation with Schistosoma haematobium. Lancet 1:1249–51.
pubmed: 4165038
doi: 10.1016/S0140-6736(67)92714-6
Gellert LL, Warrick J, Al-Ahmadie HA (2015) Urothelial carcinoma with squamous differentiation--the pathologists׳ perspective. Urol Oncol 33:437–43.
pubmed: 26321057
doi: 10.1016/j.urolonc.2015.07.018
Dotson A, May A, Davaro F, Raza SJ, Siddiqui S, Hamilton Z (2019). Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy. Int J Clin Oncol 24:706–11.
pubmed: 30707342
doi: 10.1007/s10147-019-01409-x
Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, et al (2011) Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 108:693–9.
pubmed: 21105991
doi: 10.1111/j.1464-410X.2010.09900.x
Speir RW, Barboza MP, Calaway A, Masterson TA, Cary C, Koch M, et al (2021) Role of Neoadjuvant Chemotherapy in Squamous Variant Histology in Urothelial Bladder Cancer: Does Presence and Percentage Matter? Clin Genitourin Cancer 19:47–52.
pubmed: 32711961
doi: 10.1016/j.clgc.2020.06.004
Lagwinski N, Thomas A, Stephenson AJ, Campbell S, Hoschar AP, El-Gabry E, et al (2007) Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol 31:1777–87.
pubmed: 18043032
doi: 10.1097/PAS.0b013e31805c9cd9
Ogbue O, Haddad A, Almassi N, Lapinski J, Daw H (2022) Overview of histologic variants of urothelial carcinoma: current trends and narrative review on treatment outcomes. Transl Androl Urol 11:877–901.
pubmed: 35812199
pmcid: 9262735
doi: 10.21037/tau-22-43
Nakagawa R, Iwamoto H, Makino T, Kadomoto S, Yaegashi H, Shigehara K, et al (2022) Squamous or Glandular Differentiation Predicts Poor Prognosis in pT1 Urothelial Carcinoma. In Vivo 36:2365–70.
pubmed: 36099139
pmcid: 9463927
doi: 10.21873/invivo.12968
Mitra AP, Bartsch CC, Bartsch G, Miranda G, Skinner EC, Daneshmand S (2014). Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urol Oncol 32:117–27.
pubmed: 23477878
doi: 10.1016/j.urolonc.2012.08.017
Gandhi J, Chen JF, Al-Ahmadie H (2022). Urothelial Carcinoma: Divergent Differentiation and Morphologic Subtypes. Surg Pathol Clin 15:641–59.
pubmed: 36344181
pmcid: 9756812
doi: 10.1016/j.path.2022.07.003
Mai KT, Park PC, Yazdi HM, Saltel E, Erdogan S, Stinson WA, et al (2006) Plasmacytoid urothelial carcinoma of the urinary bladder report of seven new cases. Eur Urol 50:1111–4.
pubmed: 16626859
doi: 10.1016/j.eururo.2005.12.047
Fritsche HM, Burger M, Denzinger S, Legal W, Goebell PJ, Hartmann A (2008) Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases. J Urol 180:1923–7.
pubmed: 18801525
doi: 10.1016/j.juro.2008.07.035
Kaimakliotis HZ, Monn MF, Cheng L, Masterson TA, Cary KC, Pedrosa JA, et al (2014) Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes. Urology 83:1112–6.
pubmed: 24582117
doi: 10.1016/j.urology.2013.12.035
Al-Ahmadie HA, Iyer G, Lee BH, Scott SN, Mehra R, Bagrodia A, et al (2016) Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat Genet 48:356–8.
pubmed: 26901067
pmcid: 4827439
doi: 10.1038/ng.3503
Sood S, Paner GP (2019). Plasmacytoid Urothelial Carcinoma: An Unusual Variant That Warrants Aggressive Management and Critical Distinction on Transurethral Resections. Arch Pathol Lab Med 143:1562–7.
pubmed: 30865491
doi: 10.5858/arpa.2018-0139-RS
Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, et al (2013) Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol 189:1656–61.
pubmed: 23159581
doi: 10.1016/j.juro.2012.11.084
Ricardo-Gonzalez RR, Nguyen M, Gokden N, Sangoi AR, Presti JC, McKenney JK (2012) Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for intraperitoneal spread. J Urol 187:852–5.
pubmed: 22245324
doi: 10.1016/j.juro.2011.10.145
Chung AD, Schieda N, Flood TA, Cagiannos I, Mai KT, Malone S, et al (2017) Plasmacytoid urothelial carcinoma (PUC): Imaging features with histopathological correlation. Can Urol Assoc J 11:E50–E7.
pubmed: 28163816
pmcid: 5262514
doi: 10.5489/cuaj.3789
Woo S, Ghafoor S, Das JP, Gangai N, Goh AC, Vargas HA (2022). Plasmacytoid urothelial carcinoma of the bladder: MRI features and their association with survival. Urol Oncol 40:108.e1–108.e10.
pubmed: 34750054
doi: 10.1016/j.urolonc.2021.09.017
Johansson SL, Borghede G, Holmäng S (1999) Micropapillary bladder carcinoma: a clinicopathological study of 20 cases. J Urol 161:1798–802.
pubmed: 10332438
doi: 10.1016/S0022-5347(05)68807-6
Alvarado-Cabrero I, Sierra-Santiesteban FI, Mantilla-Morales A, Hernández-Hernandez DM (2005) Micropapillary carcinoma of the urothelial tract. A clinicopathologic study of 38 cases. Ann Diagn Pathol 9:1–5.
pubmed: 15692943
doi: 10.1053/j.anndiagpath.2004.10.001
Alkibay T, Sözen S, Gürocak S, Işik Gönül I, Poyraz A, Ure I (2009) Micropapillary pattern in urothelial carcinoma: a clinicopathological analysis. Urol Int 83:300–5.
pubmed: 19829030
doi: 10.1159/000241672
Li Z, Liao H, Tan Z, Mao D, Wu Y, Xiao YM, et al (2017) Micropapillary bladder cancer: a clinico-pathological characterization and treatment analysis. Clin Transl Oncol 19:1217–24.
pubmed: 28432572
doi: 10.1007/s12094-017-1658-6
Amin MB, Ro JY, el-Sharkawy T, Lee KM, Troncoso P, Silva EG, et al (1994) Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 18:1224–32.
pubmed: 7977945
doi: 10.1097/00000478-199412000-00005
McQuitty E, Ro JY, Truong LD, Shen SS, Zhai Q, Ayala AG (2012) Lymphovascular invasion in micropapillary urothelial carcinoma: a study of 22 cases. Arch Pathol Lab Med 136:635–9.
pubmed: 22646270
doi: 10.5858/arpa.2011-0463-OA
Gaya JM, Palou J, Algaba F, Arce J, Rodríguez-Faba O, Villavicencio H (2010) The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ. Can J Urol 17:5370–6.
pubmed: 20974029
Mehrnoush V, Ismail A, Zakaria A, Elmansy H, Shahrour W, Prowse O, et al (2021) Micropapillary bladder cancer: an added indication to prophylactic urethrectomy. J Surg Case Rep 2021:rjab501.
pubmed: 34804485
pmcid: 8598118
doi: 10.1093/jscr/rjab501
Fan TW, Malhi H, Varghese B, Cen S, Hwang D, Aron M, et al (2019) Computed tomography-based texture analysis of bladder cancer: differentiating urothelial carcinoma from micropapillary carcinoma. Abdom Radiol (NY) 44:201–8.
pubmed: 30022220
doi: 10.1007/s00261-018-1694-x
Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, et al (2007) Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol 178:2302–6; discussion 7.
pubmed: 17936803
doi: 10.1016/j.juro.2007.08.038
Lopez-Beltran A, Pacelli A, Rothenberg HJ, Wollan PC, Zincke H, Blute ML, et al (1998) Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol 159:1497–503.
pubmed: 9554341
doi: 10.1097/00005392-199805000-00023
Wang J, Wang FW, Lagrange CA, Hemstreet Iii GP, Kessinger A (2010) Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma 2010.
doi: 10.1155/2010/454792
Torenbeek R, Blomjous CE, de Bruin PC, Newling DW, Meijer CJ (1994) Sarcomatoid carcinoma of the urinary bladder. Clinicopathologic analysis of 18 cases with immunohistochemical and electron microscopic findings. Am J Surg Pathol 18:241–9.
pubmed: 7509574
doi: 10.1097/00000478-199403000-00003
Sigal SH, Tomaszewski JE, Brooks JJ, Wein A, LiVolsi VA (1991) Carcinosarcoma of bladder following long-term cyclophosphamide therapy. Arch Pathol Lab Med 115:1049–51.
pubmed: 1898235
Stamatiou K, Galariotis N, Michailidis I, Petrakopoulou N, Moustou H, Zizi-Sermpetzoglou A (2010) Sarcomatoid carcinoma of the urinary bladder: a clinicopathological study of 4 cases and a review of the literature. Korean J Urol 51:724–8.
pubmed: 21031095
pmcid: 2963788
doi: 10.4111/kju.2010.51.10.724
Perret L, Chaubert P, Hessler D, Guillou L (1998) Primary heterologous carcinosarcoma (metaplastic carcinoma) of the urinary bladder: a clinicopathologic, immunohistochemical, and ultrastructural analysis of eight cases and a review of the literature. Cancer 82:1535–49.
pubmed: 9554532
doi: 10.1002/(SICI)1097-0142(19980415)82:8<1535::AID-CNCR16>3.0.CO;2-5
Murata M, Hasegawa G, Inui K, Ikeda Y, Hasegawa M, Hara N, et al (2020) Urothelial carcinoma with sarcomatoid/osteosarcoma variant of the bladder: A case report. SAGE Open Med Case Rep 8:2050313X20927615.
pubmed: 32537164
pmcid: 7268166
Young RH (1987) Carcinosarcoma of the urinary bladder. Cancer 59:1333–9.
pubmed: 3545435
doi: 10.1002/1097-0142(19870401)59:7<1333::AID-CNCR2820590717>3.0.CO;2-N
Lopez-Beltran A, Cheng L (2006) Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum Pathol 37:1371–88.
pubmed: 16949919
doi: 10.1016/j.humpath.2006.05.009
Holmäng S, Johansson SL (2001) The nested variant of transitional cell carcinoma--a rare neoplasm with poor prognosis. Scand J Urol Nephrol 35:102–5.
pubmed: 11411650
doi: 10.1080/003655901750170425
Linder BJ, Frank I, Cheville JC, Thompson RH, Thapa P, Tarrell RF, et al (2013) Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J Urol 189:1670–5.
pubmed: 23142686
doi: 10.1016/j.juro.2012.11.006
Murphy WM, Deana DG (1992) The nested variant of transitional cell carcinoma: a neoplasm resembling proliferation of Brunn’s nests. Mod Pathol 5:240–3.
pubmed: 1495929
Dhall D, Al-Ahmadie H, Olgac S (2007) Nested variant of urothelial carcinoma. Arch Pathol Lab Med 131:1725–7.
pubmed: 17979494
doi: 10.5858/2007-131-1725-NVOUC
Yamada K, Sasakura Y, Yamada S, Nagano H, Terayama K, Fujita M, et al (2020) MRI features of the nested variant of urothelial carcinoma of the urinary bladder: report of four cases. Abdom Radiol (NY) 45:2279–85.
pubmed: 32112138
doi: 10.1007/s00261-020-02442-5
Wang W, Li W, Wang K, Wu J, Qiu J, Zhang Y, et al (2023) Integrating radiomics with the vesical imaging-reporting and data system to predict muscle invasion of bladder cancer. Urol Oncol 41:294.e1–294.e8.
pubmed: 36526525
doi: 10.1016/j.urolonc.2022.10.024
Zheng Z, Xu F, Gu Z, Yan Y, Xu T, Liu S, et al (2021) Integrating multiparametric MRI radiomics features and the Vesical Imaging-Reporting and Data System (VI-RADS) for bladder cancer grading. Abdom Radiol (NY) 46:4311–23.
pubmed: 33978825
doi: 10.1007/s00261-021-03108-6
Boca B, Caraiani C, Telecan T, Pintican R, Lebovici A, Andras I, et al (2023) MRI-Based Radiomics in Bladder Cancer: A Systematic Review and Radiomics Quality Score Assessment. Diagnostics (Basel) 13.
pubmed: 37443692
doi: 10.3390/diagnostics13132300
Moribata Y, Kurata Y, Nishio M, Kido A, Otani S, Himoto Y, et al (2023) Automatic segmentation of bladder cancer on MRI using a convolutional neural network and reproducibility of radiomics features: a two-center study. Sci Rep 13:628.
pubmed: 36635425
pmcid: 9837183
doi: 10.1038/s41598-023-27883-y